Implementation of a standardized, equitable multi-omic pathway to resolve undiagnosed pediatric neurogenetic disease

Short-read genome sequencing (GS) has become a powerful first-tier test for children with suspected neurogenetic disease, yet its diagnostic yield plateaus near 40%, leaving most families without an answer. The undiagnosed remainder is not one problem but a collection of mechanistically distinct lesions, including cryptic splice-altering and regulatory variants, repeat expansions, and complex structural rearrangements, frequently missed or uninterpretable on short-read GS. Layering GS with RNA sequencing (RNA-seq) and long-read sequencing (LRS) resolves many of these cases. The central challenge is no longer whether multi-omic methods add diagnostic power, but how to deliver them as a routine, standardized, and equitable clinical service rather than an ad hoc research effort. Here we describe an integrated multi-omic diagnostic pathway built across the University of Utah and Primary Children’s Hospital for a largely rural, underserved catchment area. The pathway couples uniform GS delivery (the NeoSeq, TeleGenetics, and Gene Kids programs) with AI-assisted patient identification (Mendelian Phenotype Search Engine, MPSE) and a registry of non-diagnostic genomes subjected to multi-omic reanalysis (Neo/ReSeq). We focus on the design questions that determine whether multi-omics succeeds at scale: which modality to deploy for which patient, how source-tissue selection governs RNA-seq interpretability, how to allocate finite RNA-seq and LRS capacity, and how to embed equity so its power does not accrue only to the already-advantaged. We emphasize the architecture rather than cohort results, which are reported separately, and argue that an integrated, lifelong multi-omic strategy is the realistic path to closing the diagnostic gap in pediatric neurogenetic disease.

Authors

Institutions

Publication Details

Journal
Frontiers in Genetics
Published
2026-11-16
DOI
https://doi.org/10.3389/fgene.2026.1955129
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Implementation of a standardized, equitable multi-omic pathway to resolve undiagnosed pediatric neurogenetic disease

Pınar Bayrak‐Toydemir, Rong Mao, Rachel N. Palmquist, Steven E. Boyden et al.
1 links
Frontiers in Genetics
Genomics and Rare Diseases
article

Implementation of a standardized, equitable multi-omic pathway to resolve undiagnosed pediatric neurogenetic disease

Pınar Bayrak‐Toydemir, Rong Mao, Rachel N. Palmquist, Steven E. Boyden, Brian J. Shayota, Tanner Ellsworth, Chelsea M. Solorzano, Joselín Hernández-Ruiz, Thomas J. Nicholas, Joshua L. Bonkowsky, Shawn G. Rynearson, Makenna Beigh, Carson Holt, V. Taliercio, Steven B. Bleyl, Julie M. Porter, John Larson, Melanie Emmerson, S Malone Jenkins, Bennet Peterson, Betsy Ostrander, Barry Moore, Mark Yandell, Evy Clark, Martin Tristani-Firouzi, Hannah Happ, Marco Marchetti
article en

Abstract

Short-read genome sequencing (GS) has become a powerful first-tier test for children with suspected neurogenetic disease, yet its diagnostic yield plateaus near 40%, leaving most families without an answer. The undiagnosed remainder is not one problem but a collection of mechanistically distinct lesions, including cryptic splice-altering and regulatory variants, repeat expansions, and complex structural rearrangements, frequently missed or uninterpretable on short-read GS. Layering GS with RNA sequencing (RNA-seq) and long-read sequencing (LRS) resolves many of these cases. The central challenge is no longer whether multi-omic methods add diagnostic power, but how to deliver them as a routine, standardized, and equitable clinical service rather than an ad hoc research effort. Here we describe an integrated multi-omic diagnostic pathway built across the University of Utah and Primary Children’s Hospital for a largely rural, underserved catchment area. The pathway couples uniform GS delivery (the NeoSeq, TeleGenetics, and Gene Kids programs) with AI-assisted patient identification (Mendelian Phenotype Search Engine, MPSE) and a registry of non-diagnostic genomes subjected to multi-omic reanalysis (Neo/ReSeq). We focus on the design questions that determine whether multi-omics succeeds at scale: which modality to deploy for which patient, how source-tissue selection governs RNA-seq interpretability, how to allocate finite RNA-seq and LRS capacity, and how to embed equity so its power does not accrue only to the already-advantaged. We emphasize the architecture rather than cohort results, which are reported separately, and argue that an integrated, lifelong multi-omic strategy is the realistic path to closing the diagnostic gap in pediatric neurogenetic disease.

Frontiers in GeneticsVol. 17
Intermountain Healthcare (US), Primary Children's Hospital (US), University of Utah (US), ARUP Laboratories (United States) (US), ARUP Laboratories (United States) (US)
R. Harold Burton Foundation, Warren Alpert Foundation, Ben B. and Iris M. Margolis Foundation, University of Utah, ARUP Laboratories, National Institute for Health and Care Research, National Institutes of Health
Good health and well-being, Reduced inequalities
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon